Comparative Pharmacology
Head-to-head clinical analysis: SOMA COMPOUND W CODEINE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOMA COMPOUND W CODEINE versus WESTADONE.
SOMA COMPOUND W/ CODEINE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Soma Compound with Codeine is a combination of carisoprodol, aspirin, and codeine. Carisoprodol is a centrally acting skeletal muscle relaxant whose exact mechanism is unknown, but it is believed to act via interneuronal depression in the spinal cord and reticular formation. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg / codeine phosphate 16 mg) orally every 4-6 hours as needed for pain, not to exceed 4 tablets per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Carisoprodol: 1-2 hours. Meprobamate (active metabolite): 10-12 hours. Codeine: 2.5-3.5 hours; prolonged in renal impairment. Clinical context: steered by meprobamate half-life for repeated dosing.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Carisoprodol is hepatically metabolized; approximately 60-70% of a dose is excreted renally as meprobamate and other metabolites, with less than 1% unchanged. Codeine is renally excreted as codeine (5-17%), morphine (10-15%), and conjugates (up to 70%). Biliary/fecal elimination is minimal.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist